- Home
- NCT vs ELTX Comparison
NCT vs ELTX Comparison
Compare NCT & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCT
- ELTX
- Stock Information
- Founded
- NCT 2011
- ELTX 2011
- Country
- NCT Hong Kong
- ELTX United States
- Employees
- NCT N/A
- ELTX N/A
- Industry
- NCT
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- NCT
- ELTX Health Care
- Exchange
- NCT NYSE
- ELTX Nasdaq
- Market Cap
- NCT 114.7M
- ELTX 121.7M
- IPO Year
- NCT 2025
- ELTX N/A
- Fundamental
- Price
- NCT $3.79
- ELTX $8.05
- Analyst Decision
- NCT
- ELTX Strong Buy
- Analyst Count
- NCT 0
- ELTX 2
- Target Price
- NCT N/A
- ELTX $9.50
- AVG Volume (30 Days)
- NCT 36.5K
- ELTX 61.6K
- Earning Date
- NCT 01-01-0001
- ELTX 08-12-2025
- Dividend Yield
- NCT N/A
- ELTX N/A
- EPS Growth
- NCT N/A
- ELTX N/A
- EPS
- NCT 0.13
- ELTX N/A
- Revenue
- NCT $25,526,936.00
- ELTX N/A
- Revenue This Year
- NCT N/A
- ELTX N/A
- Revenue Next Year
- NCT N/A
- ELTX N/A
- P/E Ratio
- NCT $30.96
- ELTX N/A
- Revenue Growth
- NCT N/A
- ELTX N/A
- 52 Week Low
- NCT $3.05
- ELTX $3.34
- 52 Week High
- NCT $8.76
- ELTX $9.99
- Technical
- Relative Strength Index (RSI)
- NCT N/A
- ELTX 63.45
- Support Level
- NCT N/A
- ELTX $7.76
- Resistance Level
- NCT N/A
- ELTX $8.10
- Average True Range (ATR)
- NCT 0.00
- ELTX 0.60
- MACD
- NCT 0.00
- ELTX -0.03
- Stochastic Oscillator
- NCT 0.00
- ELTX 54.76
About NCT INTERCONT (CAYMAN) LIMITED
Intercont (Cayman) Ltd operates through its subsidiaries. It is principally engaged in the time charter service and vessel management services business.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.